News
Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...
The US Food and Drug Administration changes Covid-19 vaccine approval process. Access to seasonal boosters is restricted for ...
Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.
"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...
Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.
The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine, but with unusual ...
Trump admin's new FDA update limits annual COVID shots to high-risk groups, ending routine access for healthy kids and adults ...
COVID-19 shots for healthy younger adults and children will no longer be routinely approved under a major new policy shift unveiled Tuesday by the Trump administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results